Novel complement inhibitor limits severity of experimentally myasthenia gravis-Reference-Cited by-同舟云学术

Novel complement inhibitor limits severity of experimentally myasthenia gravis

Published:2009-02-04 Issue:1 Volume:65 Page:67-75
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Soltys Jindrich,Kusner Linda L.,Young Andrew,Richmonds Chelliah,Hatala Denise,Gong Bendi,Shanmugavel Vaithesh,Kaminski Henry J.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference37 articles.

1. Unravelling the pathogenesis of myasthenia gravis;Vincent;Nat Rev Immunol,2002

2. Myasthenia gravis: past, present, and future;Conti-Fine;J Clin Invest,2006

3. Effect of complement and its regulation on myasthenia gravis pathogenesis;Kusner;Expert Rev Clin Immunol,2008

4. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations;Engel;Mayo Clin Proc,1977

5. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients;Nakano;Neurology,1993

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis;Frontiers in Immunology;2024-06-06

2. The potential application of complement inhibitors-loaded nanosystem for autoimmune diseases via regulation immune balance;Journal of Drug Targeting;2024-03-21

3. Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future;CNS Drugs;2024-01

4. New Therapeutic Agents in Myasthenia Gravis;Journal of Multiple Sclerosis and Neuroimmunology;2023-06-30

5. Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis;Molecular Therapy - Nucleic Acids;2023-03